Oncology

Feel More Like You was developed in collaboration with Look Good, Feel Better Foundation, the leading cancer support organization focusing attention on the appearance and beauty needs of cancer patients, and Cancer Support Community, the largest professionally led, nonprofit network of cancer support worldwide.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the rapidly changing oncology market and what to look for in the drug pipeline.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

The FDA approved trifluridine/tipiracil (Lonsurf, Taiho Oncology), also known as TAS-102, as a treatment for certain adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

The risk of a solid subsequent malignant neoplasm is elevated in survivors of childhood Hodgkin lymphoma, according to an extended follow-up of more than 25 years.

Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.

HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Ibrutinub plus obinutuzumab is the first FDA-approved non-chemotherapy combination regimen for chronic lymphocytic lymphoma and small lymphocytic lymphoma.

How to treat hepatocellular carcinoma is heavily influenced by the burden of disease at diagnosis.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.

Officials with the FDA approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.

Top news of the day across the health care landscape.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, gives an overview of the exciting therapeutic developments in the B-cell lymphoma space.